Bio-Rad Laboratories (BIO) 10-Q 6 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 28, 2016
Entity Registrant Name	BIO RAD LABORATORIES INC
Entity Central Index Key	12,208
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Common Class A [Member]
Entity Common Stock, Shares Outstanding		24,271,918
Common Class B [Member]
Entity Common Stock, Shares Outstanding		5,125,441

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
ASSETS:
Cash and cash equivalents	$ 403,615	$ 457,549
Short-term investments	345,045	328,718
Restricted investments	4,210	4,210
Accounts receivable, net	381,100	391,485
Inventories:
Raw materials	115,329	109,928
Work in process	121,489	114,438
Finished goods	296,494	265,858
Total inventories	533,312	490,224
Other current assets	107,982	105,410
Total current assets	1,775,264	1,777,596
Property, plant and equipment, at cost	1,159,054	1,117,086
Less: accumulated depreciation and amortization	(709,828)	(679,396)
Property, plant and equipment, net	449,226	437,690
Goodwill, net	509,582	495,948
Purchased intangibles, net	242,264	214,026
Other investments	711,437	719,840
Other assets	65,640	64,618
Total assets	3,753,413	3,709,718
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable, accrued payroll and employee benefits	241,249	280,248
Current maturities of long-term debt and notes payable	296	298
Income and other taxes payable	27,725	29,339
Other current liabilities	131,618	131,466
Total current liabilities	400,888	441,351
Long-term debt, net of current maturities	433,980	433,883
Other long-term liabilities	374,096	343,981
Total liabilities	1,208,964	1,219,215
Stockholders' equity:
Additional paid-in capital	308,876	300,408
Retained earnings	1,820,331	1,808,055
Accumulated other comprehensive income	415,340	382,138
Total stockholders' equity	2,544,449	2,490,503
Total liabilities and stockholders' equity	3,753,413	3,709,718
Common Class A [Member]
Stockholders' equity:
Common stock	2	2
Common Class B [Member]
Stockholders' equity:
Common stock	1	1
Treasury Class A [Member]
Stockholders' equity:
Treasury Stock, Value	(12)	(12)
Treasury Class B [Member]
Stockholders' equity:
Treasury Stock, Value	$ (89)	$ (89)

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets Parenthetical - shares	Mar. 31, 2016	Dec. 31, 2015
Common Class A [Member]
Common Stock, Shares, Issued	24,271,640	24,230,448
Common Stock, Shares, Outstanding	24,271,518	24,230,326
Common Class B [Member]
Common Stock, Shares, Issued	5,126,358	5,130,558
Common Stock, Shares, Outstanding	5,125,441	5,129,641
Treasury Class A [Member]
Treasury Stock, Shares	122	122
Treasury Class B [Member]
Treasury Stock, Shares	917	917

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net sales	$ 471,197	$ 472,821
Cost of goods sold	207,168	202,715
Gross profit	264,029	270,106
Selling, general and administrative expense	189,716	188,555
Research and Development Expense	48,586	47,202
Segment profit (loss)	25,727	34,349
Interest expense	5,580	5,002
Foreign exchange losses, net	1,129	3,806
Other (income) expense, net	(1,177)	(1,153)
Income before income taxes	20,195	26,694
Provision for income taxes	(7,919)	(8,876)
Net income including noncontrolling interests	12,276	17,818
Net income attributable to Bio-Rad	$ 12,276	$ 17,818
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 0.42	$ 0.61
Weighted average common shares - basic	29,364	29,092
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 0.42	$ 0.61
Weighted average common shares - diluted	29,506	29,289

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net Income (Loss) Attributable to Parent	$ 12,276	$ 17,818
Foreign currency translation adjustments	37,935	(19,470)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	(640)	1,041
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense	(4,093)	6,930
Total other comprehensive income (loss) net of tax	33,202	(11,499)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ 45,478	$ 6,319

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Cash received from customers	$ 492,407	$ 478,479
Cash paid to suppliers and employees	(508,820)	(453,986)
Interest (paid) received, net	(187)	471
Income tax refunds, net	10,421	1,503
Investment proceeds and miscellaneous receipts, net	1,667	1,175
Excess tax benefits from share-based compensation	(67)	(1,212)
(Payments for) proceeds from forward foreign exchange contracts, net	(2,869)	3,016
Net cash (used in) provided by operating activities	(7,448)	29,446
Cash flows from investing activities:
Capital expenditures	(25,296)	(27,080)
Proceeds from dispositions of property, plant and equipment	1	4
Payments for acquisition and long-term investment	(9,634)	(895)
Payments for purchases of intangible assets	0	(1,307)
Payments for purchases of marketable securities and investments	(71,485)	(66,568)
Proceeds from sales of marketable securities and investments	20,381	27,356
Proceeds from maturities of marketable securities and investments	35,175	40,499
Net cash used in investing activities	(50,858)	(27,991)
Cash flows from financing activities:
Payments on long-term borrowings	(77)	(66)
Payments of contingent consideration	(3,500)	(2,983)
Proceeds from issuance of common stock for shared-based compensation	3,768	1,506
Excess tax benefits from share-based compensation	67	1,212
Net cash provided by (used in) financing activities	258	(331)
Effect of foreign exchange rate changes on cash	4,114	11,353
Net (decrease) increase in cash and cash equivalents	(53,934)	12,477
Cash and cash equivalents at beginning of period	457,549	413,251
Cash and cash equivalents at end of period	403,615	425,728
Adjustments to Reconcile Net Income to Cash Provided by Operating Activities [Abstract]
Net income	12,276	17,818
Adjustments, Noncash Items, to Reconcile Net Income to Cash Provided by Operating Activities [Abstract]
Depreciation and amortization	34,090	32,283
Share-based compensation	4,645	4,071
Losses (gains) on dispositions of securities	229	(214)
Excess tax benefits from share-based compensation	(67)	(1,212)
Changes in fair value of contingent consideration	(1,284)	(1,192)
Decrease in accounts receivable	19,991	15,567
Increase in inventories	(34,400)	(29,469)
Increase in other current assets	(15,730)	(5,076)
Decrease in accounts payable and other current liabilities	(47,666)	(7,747)
Increase in income taxes payable	14,075	6,106
Net decrease/increase in other long-term assets/liabilities	6,393	(1,489)
Net cash (used in) provided by operating activities	$ (7,448)	$ 29,446

1. Organization, Consolidation

1. Organization, Consolidation and Presentation of Financial Statements	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure	1. BASIS OF PRESENTATION AND USE OF ESTIMATES Basis of Presentation In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2015 . We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Recent Accounting Standards Updates In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and early adoption is permitted. We are currently evaluating the effect ASU 2016-09 will have on our consolidated financial statements. In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that doesn’t consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. ASU 2016-07 will be applied on a prospective basis and is effective for all entities for fiscal years beginning after December 15, 2016, and interim periods within those years and early adoption is permitted. We do not plan to early adopt ASU 2016-07 and currently do not expect it to affect our consolidated financial statements when adopted on January 1, 2017. In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently evaluating the effect ASU 2016-02 will have on our consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-01 will have, if any, on our consolidated financial statements. In September 2015, the FASB issued ASU 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments," which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Under ASU 2015-16, acquirers must recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The measurement period cannot exceed one year from the date of the acquisition. ASU 2015-16 was effective on January 1, 2016, and we adopted it at the same time as a change in accounting policy. For the first quarter of 2016, ASU 2015-16 had no effect on our consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods therein, with early adoption permitted. We will not early adopt. We are currently evaluating the effect ASU 2015-11 will have, if any, on our consolidated financial statements. In April 2015, the FASB issued ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 was issued to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. This makes the presentation of debt issuance costs consistent with the presentation of debt discounts or premiums. Under prior U.S. GAAP, debt issuance costs were reported on the balance sheet as assets and amortized as interest expense. Under ASU 2015-03, debt issuance costs will continue to be amortized to interest expense using the effective interest method. In August 2015, the FASB issued ASU 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" to clarify the SEC staff’s position that it would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, which is our current practice. We adopted ASU 2015-03 on January 1, 2016 on a retrospective basis as a change in accounting policy. The Condensed Consolidated Balance Sheet as of December 31, 2015, was retrospectively adjusted by decreasing Other assets and Long-term debt, net of current maturities by $1.8 million , respectively. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, The FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-10 and 2016-08 on January 1, 2018. We are currently evaluating the effect that these ASUs will have on our consolidated financial statements and related disclosures.

2. Acquisitions

2. Acquisitions	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	2. ACQUISITIONS Propel Labs, Inc. In January 2016, we acquired a high performance analytical flow cytometer platform from Propel Labs (Propel) that will enable advanced and novice users to perform basic and multi-parameter cytometry for a wide range of applications and chemistries. This asset acquisition was accounted for as a business combination, as the new analytical flow cytometer platform represented an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return and therefore constitutes a business in accordance with GAAP. The amount of the acquisition-related cost was minimal as Bio-Rad primarily represented itself during the acquisition process. This business acquisition is included in our Life Science segment’s results of operations from the acquisition date. The preliminary fair value of the consideration as of the acquisition date was $38.8 million , which included $9.5 million paid in cash at the closing date and $29.3 million in contingent consideration potentially payable to Propel’s shareholders. The contingent consideration was based on a probability-weighted income approach related to the achievement of certain sales milestones, and was recognized at its estimated fair value of $29.3 million as of March 31, 2016. (See Note 3, "Fair Value Measurements" in the Notes to Condensed Consolidated Financial Statements of Part I, Item 1 of this Quarterly Report on Form 10-Q for further discussion of the contingent consideration valuation and underlying assumptions.) The purchase accounting for this acquisition is preliminary and subject to revision, as more time is needed to transfer information necessary from the seller and include it into a comprehensive valuation of certain assets and compensatory services. The preliminary fair values of the net assets acquired from Propel as of the acquisition date were determined to be $36.0 million of definite-lived intangible assets and $2.8 million of goodwill. Measurement-period adjustments will be recorded as soon as they are determined in accordance with ASU 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments." We expect the goodwill recorded to be deductible for income tax purposes. The acquired analytical flow cytometer platform fits well into Bio-Rad’s existing Life Science segment product offerings and may offer researchers greater access to this technology. In addition to the sales milestones, Bio-Rad and Propel negotiated development milestone payments concurrent with and included in the purchase agreement. Bio-Rad is receiving future manufacturing, engineering and marketing support from Propel on which payments of the milestones are upon the successful completion of all contracted services. As a result, these development milestones are not included in the total purchase consideration and a majority will be expensed in future periods.

3. Fair Value Measurements

3. Fair Value Measurements	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. FAIR VALUE MEASUREMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1: Quoted prices in active markets for identical instruments • Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) • Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2016 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 35.6 $ — $ 35.6 U.S. government sponsored agencies — 5.4 — 5.4 Foreign time deposits 9.8 — — 9.8 Money market funds 4.3 — — 4.3 Total cash equivalents (a) 14.1 41.0 — 55.1 Restricted investment: 4.2 — — 4.2 Available-for-sale investments: Corporate debt securities — 149.8 — 149.8 U.S. government sponsored agencies — 78.5 — 78.5 Foreign government obligations — 5.0 — 5.0 Municipal obligations — 10.1 — 10.1 Marketable equity securities 653.6 — — 653.6 Asset-backed securities — 68.6 — 68.6 Total available-for-sale investments (b) 653.6 312.0 — 965.6 Forward foreign exchange contracts (c) — 0.9 — 0.9 Total financial assets carried at fair value $ 671.9 $ 353.9 $ — $ 1,025.8 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (d) $ — $ 2.4 $ — $ 2.4 Contingent consideration (e) — — 43.6 43.6 Total financial liabilities carried at fair value $ — $ 2.4 $ 43.6 $ 46.0 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2015 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 33.2 $ — $ 33.2 Foreign government obligations — 0.6 — 0.6 Foreign time deposits 11.9 — — 11.9 U.S. government sponsored agencies — 14.6 — 14.6 Money market funds 11.3 — — 11.3 Total cash equivalents (a) 23.2 48.4 — 71.6 Restricted investment: 4.2 — — 4.2 Available-for-sale investments: Corporate debt securities — 156.9 — 156.9 U.S. government sponsored agencies — 74.8 — 74.8 Foreign government obligations — 4.6 — 4.6 Municipal obligations — 6.4 — 6.4 Marketable equity securities 660.1 — — 660.1 Asset-backed securities — 54.8 — 54.8 Total available-for-sale investments (b) 660.1 297.5 — 957.6 Forward foreign exchange contracts (c) — 0.9 — 0.9 Total financial assets carried at fair value $ 687.5 $ 346.8 $ — $ 1,034.3 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (d) $ — $ 1.1 $ — $ 1.1 Contingent consideration (e) — — 19.1 19.1 Total financial liabilities carried at fair value $ — $ 1.1 $ 19.1 $ 20.2 (a) Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. (b) Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, December 31, 2015 Short-term investments $ 345.0 $ 328.7 Other investments 620.6 628.9 Total $ 965.6 $ 957.6 (c) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. (d) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. (e) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2016 December 31, 2015 Other current liabilities $ 14.3 $ 13.5 Other long-term liabilities 29.3 5.6 Total $ 43.6 $ 19.1 In 2012, we recognized a contingent consideration liability for certain milestones of $44.6 million upon our acquisition of a new cell sorting system from Propel. Since 2012, we have paid $28.9 million upon reaching the milestones and have reduced the valuation of the milestones by $11.4 million to its estimated fair value of $4.3 million as of March 31, 2016 . During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a new high performance analytical flow cytometer platform from Propel. At the acquisition date, the contingent consideration was based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020 . The sales milestones could potentially range from $0 to an unlimited amount through December 31, 2020 . The contingent consideration was recognized at its estimated fair value of $29.3 million as of March 31, 2016 . The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the three months ended March 31, 2016 (in millions): 2016 January 1 $ 9.1 Cell sorting system: Payment of sales milestone (3.5 ) Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (1.3 ) Analytical flow cytometer platform: Acquisition of high performance analytical flow cytometer platform 29.3 March 31 $ 33.6 The following table provides quantitative information about Level 3 inputs for fair value measurement of our cell sorting system and analytical flow cytometer platform contingent consideration liabilities as of March 31, 2016 . Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement. Range Valuation Technique Unobservable Input From To Cell sorting system Probability-weighted income approach Sales milestones: Credit adjusted discount rates 0.68% N/A Projected volatility of growth rate 15% N/A Market price of risk 1.30% N/A Analytical flow cytometer platform Probability-weighted income approach Sales milestones: Market price of risk 6 % Volatility 10 % In 2014, we recognized a contingent consideration liability upon our acquisition of GnuBIO. The contingent consideration for the milestones was valued at $10.7 million at the acquisition date based on assumptions regarding the probability of achieving the milestones, with such amounts discounted to present value. The Level 3 contingent consideration was revalued to a fair value of $10.0 million as of March 31, 2016 and December 31, 2015 . To estimate the fair value of Level 2 debt securities as of March 31, 2016 and December 31, 2015 , our primary pricing provider uses S&P Capital IQ as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. The chosen pricing hierarchy for our Level 2 securities, other than certificates of deposit and commercial paper, is S&P Capital IQ as the primary pricing source and then our custodian as the secondary pricing source. If S&P Capital IQ does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing. For commercial paper as of March 31, 2016 and December 31, 2015 , pricing is determined by a straight-line calculation, starting with the purchase price on the date of purchase and increasing to par at maturity. Interest bearing certificates of deposit and commercial paper are priced at par. In addition to the above, our primary pricing provider performs daily reasonableness testing of the S&P Capital IQ prices to custodian reported prices. Prices outside a tolerable variance of approximately 1% are investigated and resolved. Available-for-sale investments consist of the following (in millions): March 31, 2016 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 149.3 $ 0.7 $ (0.2 ) $ 149.8 Municipal obligations 10.0 0.1 — 10.1 Asset-backed securities 68.4 0.1 (0.2 ) 68.3 U.S. government sponsored agencies 77.8 0.7 — 78.5 Foreign government obligations 5.0 — — 5.0 Marketable equity securities 31.2 2.7 (0.6 ) 33.3 341.7 4.3 (1.0 ) 345.0 Long-term investments: Marketable equity securities 54.5 565.8 — 620.3 Asset-backed securities 0.3 — — 0.3 54.8 565.8 — 620.6 Total $ 396.5 $ 570.1 $ (1.0 ) $ 965.6 December 31, 2015 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 157.2 $ 0.1 $ (0.4 ) $ 156.9 Municipal obligations 6.4 — — 6.4 Asset-backed securities 54.8 — (0.2 ) 54.6 U.S. government sponsored agencies 74.9 0.1 (0.2 ) 74.8 Foreign government obligations 4.6 — — 4.6 Marketable equity securities 29.4 2.7 (0.7 ) 31.4 327.3 2.9 (1.5 ) 328.7 Long-term investments: Marketable equity securities 54.5 574.2 — 628.7 Asset-backed securities 0.3 — (0.1 ) 0.2 54.8 574.2 (0.1 ) 628.9 Total $ 382.1 $ 577.1 $ (1.6 ) $ 957.6 The unrealized gains of our long-term marketable equity securities are primarily due to our investment in Sartorius AG preferred shares. The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): March 31, December 31, 2015 Fair value of investments in a loss position 12 months or more $ 9.5 $ 10.4 Fair value of investments in a loss position less than 12 months $ 97.6 $ 204.0 Gross unrealized losses for investments in a loss position 12 months or more $ 0.3 $ 0.4 Gross unrealized losses for investments in a loss position less than 12 months $ 0.7 $ 1.2 The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others. Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at March 31, 2016 or at December 31, 2015 . As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of March 31, 2016 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income. The following is a summary of our forward foreign exchange contracts (in millions): March 31, 2016 Contracts maturing in April through June 2016 to sell foreign currency: Notional value $ 16.1 Unrealized gain $ 0.1 Contracts maturing in April through June 2016 to purchase foreign currency: Notional value $ 337.2 Unrealized loss $ (1.6 ) The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2016 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 101.3 $ 101.4 Mature in one to five years 154.4 154.8 Mature in more than five years 55.1 55.8 Total $ 310.8 $ 312.0 The estimated fair value of financial instruments that are not recognized at fair value in the Condensed Consolidated Balance Sheets and are included in Other investments, are presented in the table below. Fair value has been determined using significant observable inputs, including quoted prices in active markets for similar instruments. Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value. The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value. Other investments include financial instruments, the majority of which have fair value based on similar, actively traded stock adjusted for various discounts, including a discount for marketability. Long-term debt, excluding leases and current maturities, has an estimated fair value based on quoted market prices for the same or similar issues. The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): March 31, 2016 December 31, 2015 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Other investments $ 86.5 $ 831.8 2 $ 86.5 $ 843.2 2 Total long-term debt, excluding leases and current maturities $ 422.0 $ 455.6 2 $ 421.9 $ 454.3 2 We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own over 35% of the outstanding voting shares (excluding treasury shares) of Sartorius as of March 31, 2016 . The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius’ Board of Directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. We account for this investment using the cost method. The carrying value of this investment is included in Other investments in our Condensed Consolidated Balance Sheets. As the stock is thinly traded and in conjunction with the valuation method discussed above, we have classified the estimated fair value as Level 2. The Level 2 classification is appropriate given the valuation method employed, which incorporates an observable input of the fair value of the Sartorius’ actively traded preferred stock.

4. Intangible Assets, Goodwill

4. Intangible Assets, Goodwill and Other	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	4. GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment were as follows (in millions): Life Science Clinical Diagnostics Total Balances as of January 1, 2016: Goodwill $ 207.2 $ 316.9 $ 524.1 Accumulated impairment losses (27.2 ) (1.0 ) (28.2 ) Goodwill, net 180.0 315.9 495.9 Acquisitions 2.8 — 2.8 Currency fluctuations 0.5 10.4 10.9 Balances as of March 31, 2016: Goodwill 210.5 327.3 537.8 Accumulated impairment losses (27.2 ) (1.0 ) (28.2 ) Goodwill, net $ 183.3 $ 326.3 $ 509.6 In conjunction with the purchase of certain assets from Propel in January 2016 (see Note 2, "Acquisitions" in the Notes to Condensed Consolidated Financial Statements of Part I, Item 1 of this Quarterly Report on Form 10-Q), we recorded $2.8 million of goodwill and $36.0 million of definite-lived intangible assets: $33.0 million of developed product technology and $3.0 million of covenants not to compete. Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): March 31, 2016 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 2-9 $ 88.3 $ (50.4 ) $ 37.9 Know how 1-10 187.6 (129.8 ) 57.8 Developed product technology 3-13 134.9 (52.1 ) 82.8 Licenses 3-10 39.6 (29.2 ) 10.4 Tradenames 5-8 3.6 (2.5 ) 1.1 Covenants not to compete 3-10 7.8 (1.9 ) 5.9 Total definite-lived intangible assets 461.8 (265.9 ) 195.9 In-process research and development 46.4 — 46.4 Total purchased intangible assets $ 508.2 $ (265.9 ) $ 242.3 December 31, 2015 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 2-10 $ 84.7 $ (46.8 ) $ 37.9 Know how 1-10 184.0 (121.6 ) 62.4 Developed product technology 4-12 101.3 (48.9 ) 52.4 Licenses 3-10 39.2 (28.5 ) 10.7 Tradenames 5-9 3.5 (2.4 ) 1.1 Covenants not to compete 3-7 4.8 (1.7 ) 3.1 Total definite-lived intangible assets 417.5 (249.9 ) 167.6 In-process research and development 46.4 — 46.4 Total purchased intangible assets $ 463.9 $ (249.9 ) $ 214.0 Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended March 31, 2016 2015 Amortization expense $ 9.4 $ 9.2

5. Product Warranty Liability

5. Product Warranty Liability	3 Months Ended
	Mar. 31, 2016
Product Warranties Disclosures [Abstract]
Product Warranty Liability	5. PRODUCT WARRANTY LIABILITY We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon delivery of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. A review is performed on a quarterly basis to assess the adequacy of our warranty accrual. Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions): January 1, 2016 $ 17.4 Provision for warranty 8.1 Actual warranty costs (7.4 ) March 31, 2016 $ 18.1

6. Long-Term Debt

6. Long-Term Debt	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Long-term Debt	6. LONG-TERM DEBT The principal components of long-term debt are as follows (in millions): March 31, December 31, 2015 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (3.0 ) (3.1 ) Long-term debt less unamortized discount and debt issuance costs 422.0 421.9 Capital leases and other debt 12.3 12.3 434.3 434.2 Less current maturities (0.3 ) (0.3 ) Long-term debt $ 434.0 $ 433.9 Senior Notes due 2020 In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due 2020 ( 4.875% Notes). The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946% . The 4.875% Notes pay a fixed rate of interest of 4.875% per year. We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness. Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios. Credit Agreement In June 2014, Bio-Rad entered into a $200.0 million unsecured Credit Agreement, replacing the Amended and Restated Credit Agreement of June 2010, which expired on June 21, 2014. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of March 31, 2016 or December 31, 2015 , however $0.8 million was utilized for domestic standby letters of credit that reduced our borrowing availability. The Credit Agreement matures in June 2019 . If we had borrowed against our Credit Agreement, the borrowing rate would have been 1.88% at March 31, 2016 . The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of March 31, 2016 .

7. Accumulated Other Comprehen

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)	3 Months Ended
	Mar. 31, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	7. ACCUMULATED OTHER COMPREHENSIVE INCOME Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding losses on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2016: $ 33.7 $ (20.7 ) $ 369.1 $ 382.1 Other comprehensive income (loss), before reclassifications 37.9 (0.9 ) (6.5 ) 30.5 Amounts reclassified from Accumulated other comprehensive income — 0.3 — 0.3 Income tax effects — — 2.4 2.4 Other comprehensive income (loss), net of income taxes 37.9 (0.6 ) (4.1 ) 33.2 Balances as of March 31, 2016: $ 71.6 $ (21.3 ) $ 365.0 $ 415.3 Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2015: $ 71.2 $ (16.3 ) $ 164.0 $ 218.9 Other comprehensive (loss) income, before reclassifications (19.5 ) 0.9 11.2 (7.4 ) Amounts reclassified from Accumulated other comprehensive income — 0.2 (0.3 ) (0.1 ) Income tax effects — — (4.0 ) (4.0 ) Other comprehensive (loss) income, net of income taxes (19.5 ) 1.1 6.9 (11.5 ) Balances as of March 31, 2015: $ 51.7 $ (15.2 ) $ 170.9 $ 207.4 The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows: Income before taxes impact (in millions): Three Months Ended March 31, Components of Comprehensive income 2016 2015 Location Amortization of foreign other post-employment benefit items $ (0.3 ) $ (0.2 ) Selling, general and administrative expense Net holding gains on available-for-sale investments $ — $ 0.3 Other (income) expense, net Reclassification adjustments are calculated using the specific identification method.

8. Earnings Per Share

8. Earnings Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share	8. EARNINGS PER SHARE Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended March 31, 2016 2015 Basic weighted average shares outstanding 29,364 29,092 Effect of potentially dilutive stock options and restricted stock awards 142 197 Diluted weighted average common shares 29,506 29,289 Anti-dilutive shares 90 106

9. Other Income and Expenses

9. Other Income and Expenses	3 Months Ended
	Mar. 31, 2016
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	9. OTHER INCOME AND EXPENSE, NET Other (income) expense, net includes the following components (in millions): Three Months Ended March 31, 2016 2015 Interest and investment income $ (1.2 ) $ (0.9 ) Net realized gain on investments — (0.3 ) Other (income) expense, net $ (1.2 ) $ (1.2 )

10. Income Taxes

10. Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	10. INCOME TAXES Our effective income tax rate was 39% and 33% for the three months ended March 31, 2016 and 2015 , respectively. The effective tax rate for the first quarter of 2016 was higher primarily due to losses incurred in certain foreign jurisdictions for which no income tax benefit was expected and an increase in taxes partly due to newly enacted tax rates in certain foreign jurisdictions. Our foreign taxes result primarily from income earned in France and Switzerland. Many jurisdictions in which we operate including Switzerland, Russia, the U.K. and Singapore have statutory tax rates that are significantly lower than the U.S. statutory tax rate of 35% . Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits. Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. As of March 31, 2016 , based on the expected outcome of certain examinations or as a result of the expiration of statute of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $4 million . Substantially all such amounts will impact our effective income tax rate.

11. Segment Information

11. Segment Information	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Segment Information	11. SEGMENT INFORMATION Information regarding industry segments for the three months ended March 31, 2016 and 2015 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2016 $ 165.9 $ 301.7 $ 3.6 2015 $ 155.9 $ 313.6 $ 3.3 Segment net (loss) profit 2016 $ (3.3 ) $ 24.8 $ 0.3 2015 $ (2.4 ) $ 35.2 $ (0.1 ) Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. The following reconciles total segment profit to consolidated income before taxes (in millions): Three Months Ended March 31, 2016 2015 Total segment profit $ 21.8 $ 32.7 Foreign currency exchange losses, net (1.1 ) (3.8 ) Net corporate operating, interest and other expense not allocated to segments (1.7 ) (3.4 ) Other income (expense), net 1.2 1.2 Consolidated income before income taxes $ 20.2 $ 26.7

12. Legal Proceedings

12. Legal Proceedings	3 Months Ended
	Mar. 31, 2016
Loss Contingency, Information about Litigation Matters [Abstract]
Legal Proceedings.	12. LEGAL PROCEEDINGS On January 23, 2015, the City of Riviera Beach General Employees’ Retirement System filed a shareholder derivative lawsuit in the Superior Court of California, Contra Costa County, against three of our current directors and one former director. We are also named as a nominal defendant. In the complaint, the plaintiff alleges that our directors breached their fiduciary duty of loyalty by failing to ensure that we had sufficient internal controls and systems for compliance with the Foreign Corrupt Practices Act ("FCPA"); that we failed to provide adequate training on the FCPA; and that based on these actions, the directors have been unjustly enriched. Purportedly seeking relief on our behalf, the plaintiff seeks an award of restitution and unspecified damages, costs and expenses (including attorneys’ fees). On April 23, 2015, we and the individual defendants filed a demurrer requesting dismissal of the complaint in this case. The demurrer was heard on August 6, 2015, and the Court granted the demurrer for failure to make a demand on our Board of Directors on August 17, 2015, but provided leave to amend. On September 4, 2015, the plaintiff filed an amended complaint and simultaneously served a litigation demand letter on our Board of Directors via its counsel in this action. The letter demands that we investigate and bring appropriate legal action against certain individuals, including the defendants in the City of Riviera Beach case and six current and former employees. The plaintiff also moved for a temporary stay in the proceedings, purportedly to enable the Board to respond to the demand. The Board formed a Demand Review Committee to respond to the demand. On February 24, 2016, the Demand Review Committee reported to the Board that it had concluded its investigation and unanimously determined that it is not in the best interests of the Company and its stockholders to pursue litigation against any individuals named in the City of Riviera Beach’s litigation demand letter. On October 6, 2015, we and the individual defendants filed a second demurrer, seeking to dismiss the case for failure to make a timely pre-suit demand. The case has been stayed pending mediation. The caption is City of Riviera Beach General Employees’ Retirement System v. Schwartz et al., Case No. C-15-00140. On August 13, 2015 and August 18, 2015, respectively, each of International Brotherhood of Electrical Workers Local 38 Pension Fund and Wayne County Employees’ Retirement System filed a stockholder derivative complaint in the Delaware Court of Chancery against four of our current directors and one former director. We are named as a nominal defendant in the complaints. The complaints allege that the defendants failed to cause us to develop internal controls sufficient to ensure our compliance with the FCPA. The plaintiffs assert claims for breach of fiduciary duty and unjust enrichment and request an award of the damages we sustained as a result of the alleged violations, among other relief. The two lawsuits were consolidated on August 27, 2015. The case has been stayed pending mediation. The caption of the consolidated case is In re Bio-Rad Laboratories, Inc. Stockholder Litigation, Consol. C.A. No. 11387-VCN (Del. Ch.). On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our current directors and one former director. The plaintiff’s suit alleges whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleges wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff seeks back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. We believe this lawsuit is without merit, and on July 28, 2015 we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. Discovery has started. A mediation occurred on April 19, 2016 and did not result in settlement. Trial is scheduled for January 9, 2017. We are vigorously defending against the claims above. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability. In addition, we are party to various other claims, legal actions and complaints arising in the ordinary course of business. We do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity. However, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

1. Basis of Presentation and U

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Policies)	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2016-09, "Improvements to Employee Share-Based Payment Accounting." ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and early adoption is permitted. We are currently evaluating the effect ASU 2016-09 will have on our consolidated financial statements. In March 2016, the FASB issued ASU 2016-07, "Simplifying the Transition to the Equity Method of Accounting," which eliminates the requirement to retrospectively apply the equity method in previous periods when an investor initially obtains significant influence over an investee. Under current guidance, an investor that doesn’t consolidate an investment and initially accounts for it under a method other than the equity method is required to retrospectively apply the equity method in prior periods in which it held the investment when it subsequently obtained significant influence. ASU 2016-07 will be applied on a prospective basis and is effective for all entities for fiscal years beginning after December 15, 2016, and interim periods within those years and early adoption is permitted. We do not plan to early adopt ASU 2016-07 and currently do not expect it to affect our consolidated financial statements when adopted on January 1, 2017. In February 2016, the FASB issued ASU 2016-02, "Leases," which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. We do not plan to early adopt. ASU 2016-02 will be adopted on a modified retrospective basis, with elective reliefs, which requires application of ASU 2016-02 for all periods presented. We are currently evaluating the effect ASU 2016-02 will have on our consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification, for which changes in fair value are reported in other comprehensive income, for equity securities with readily determinable fair values. For equity investments without readily determinable fair values, the cost method is also eliminated. However, entities will be able to elect to record equity investments without readily determinable fair values at cost, less impairment, and plus or minus subsequent adjustments for observable price changes. Changes in the basis of these equity investments will be reported in current earnings. ASU 2016-01 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-01 will have, if any, on our consolidated financial statements. In September 2015, the FASB issued ASU 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments," which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. Under ASU 2015-16, acquirers must recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The measurement period cannot exceed one year from the date of the acquisition. ASU 2015-16 was effective on January 1, 2016, and we adopted it at the same time as a change in accounting policy. For the first quarter of 2016, ASU 2015-16 had no effect on our consolidated financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” Under current guidance, an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). ASU 2015-11 eliminates this analysis and requires entities to measure most inventory “at the lower of cost and NRV.” ASU 2015-11 is effective prospectively for annual periods beginning after December 15, 2016, and interim periods therein, with early adoption permitted. We will not early adopt. We are currently evaluating the effect ASU 2015-11 will have, if any, on our consolidated financial statements. In April 2015, the FASB issued ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs." ASU 2015-03 was issued to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. This makes the presentation of debt issuance costs consistent with the presentation of debt discounts or premiums. Under prior U.S. GAAP, debt issuance costs were reported on the balance sheet as assets and amortized as interest expense. Under ASU 2015-03, debt issuance costs will continue to be amortized to interest expense using the effective interest method. In August 2015, the FASB issued ASU 2015-15, "Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements" to clarify the SEC staff’s position that it would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, which is our current practice. We adopted ASU 2015-03 on January 1, 2016 on a retrospective basis as a change in accounting policy. The Condensed Consolidated Balance Sheet as of December 31, 2015, was retrospectively adjusted by decreasing Other assets and Long-term debt, net of current maturities by $1.8 million , respectively. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers,” which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In August 2015, the FASB issued ASU 2015-14 to defer the effective date for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is permitted as of the original effective date in ASU 2014-09, which is annual reporting periods beginning after December 15, 2016, however, we will not early adopt. In April 2016, the FASB issued ASU 2016-10, "Identifying Performance Obligations and Licensing," which amends the guidance in ASU 2014-09 on accounting for licenses of intellectual property and identifying performance obligations. In March 2016, The FASB issued ASU 2016-08, "Principal versus Agent Considerations (Reporting Revenue Gross versus Net)," which amends the principal versus agent guidance in ASU 2014-09. The standards are to be applied retrospectively and permit the use of either the retrospective or cumulative effect transition method. We will use the cumulative effect transition method once we adopt ASUs 2014-09, 2016-10 and 2016-08 on January 1, 2018. We are currently evaluating the effect that these ASUs will have on our consolidated financial statements and related disclosures.

3. Fair Value Measurements (Ta

3. Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Schedule of financial assets and liabilities carried at fair value on a recurring basis	Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2016 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 35.6 $ — $ 35.6 U.S. government sponsored agencies — 5.4 — 5.4 Foreign time deposits 9.8 — — 9.8 Money market funds 4.3 — — 4.3 Total cash equivalents (a) 14.1 41.0 — 55.1 Restricted investment: 4.2 — — 4.2 Available-for-sale investments: Corporate debt securities — 149.8 — 149.8 U.S. government sponsored agencies — 78.5 — 78.5 Foreign government obligations — 5.0 — 5.0 Municipal obligations — 10.1 — 10.1 Marketable equity securities 653.6 — — 653.6 Asset-backed securities — 68.6 — 68.6 Total available-for-sale investments (b) 653.6 312.0 — 965.6 Forward foreign exchange contracts (c) — 0.9 — 0.9 Total financial assets carried at fair value $ 671.9 $ 353.9 $ — $ 1,025.8 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (d) $ — $ 2.4 $ — $ 2.4 Contingent consideration (e) — — 43.6 43.6 Total financial liabilities carried at fair value $ — $ 2.4 $ 43.6 $ 46.0 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2015 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial Assets Carried at Fair Value: Cash equivalents: Commercial paper $ — $ 33.2 $ — $ 33.2 Foreign government obligations — 0.6 — 0.6 Foreign time deposits 11.9 — — 11.9 U.S. government sponsored agencies — 14.6 — 14.6 Money market funds 11.3 — — 11.3 Total cash equivalents (a) 23.2 48.4 — 71.6 Restricted investment: 4.2 — — 4.2 Available-for-sale investments: Corporate debt securities — 156.9 — 156.9 U.S. government sponsored agencies — 74.8 — 74.8 Foreign government obligations — 4.6 — 4.6 Municipal obligations — 6.4 — 6.4 Marketable equity securities 660.1 — — 660.1 Asset-backed securities — 54.8 — 54.8 Total available-for-sale investments (b) 660.1 297.5 — 957.6 Forward foreign exchange contracts (c) — 0.9 — 0.9 Total financial assets carried at fair value $ 687.5 $ 346.8 $ — $ 1,034.3 Financial Liabilities Carried at Fair Value: Forward foreign exchange contracts (d) $ — $ 1.1 $ — $ 1.1 Contingent consideration (e) — — 19.1 19.1 Total financial liabilities carried at fair value $ — $ 1.1 $ 19.1 $ 20.2 (a) Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. (b) Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, December 31, 2015 Short-term investments $ 345.0 $ 328.7 Other investments 620.6 628.9 Total $ 965.6 $ 957.6 (c) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. (d) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. (e) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2016 December 31, 2015 Other current liabilities $ 14.3 $ 13.5 Other long-term liabilities 29.3 5.6 Total $ 43.6 $ 19.1
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a reconciliation of the Level 3 cell sorting system and analytical flow cytometer platform contingent consideration liabilities measured at estimated fair value based on original valuations and updated quarterly for the three months ended March 31, 2016 (in millions): 2016 January 1 $ 9.1 Cell sorting system: Payment of sales milestone (3.5 ) Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (1.3 ) Analytical flow cytometer platform: Acquisition of high performance analytical flow cytometer platform 29.3 March 31 $ 33.6
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	The following table provides quantitative information about Level 3 inputs for fair value measurement of our cell sorting system and analytical flow cytometer platform contingent consideration liabilities as of March 31, 2016 . Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement. Range Valuation Technique Unobservable Input From To Cell sorting system Probability-weighted income approach Sales milestones: Credit adjusted discount rates 0.68% N/A Projected volatility of growth rate 15% N/A Market price of risk 1.30% N/A Analytical flow cytometer platform Probability-weighted income approach Sales milestones: Market price of risk 6 % Volatility 10 %
Schedule of available-for-sale investments	Available-for-sale investments consist of the following (in millions): March 31, 2016 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 149.3 $ 0.7 $ (0.2 ) $ 149.8 Municipal obligations 10.0 0.1 — 10.1 Asset-backed securities 68.4 0.1 (0.2 ) 68.3 U.S. government sponsored agencies 77.8 0.7 — 78.5 Foreign government obligations 5.0 — — 5.0 Marketable equity securities 31.2 2.7 (0.6 ) 33.3 341.7 4.3 (1.0 ) 345.0 Long-term investments: Marketable equity securities 54.5 565.8 — 620.3 Asset-backed securities 0.3 — — 0.3 54.8 565.8 — 620.6 Total $ 396.5 $ 570.1 $ (1.0 ) $ 965.6 December 31, 2015 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 157.2 $ 0.1 $ (0.4 ) $ 156.9 Municipal obligations 6.4 — — 6.4 Asset-backed securities 54.8 — (0.2 ) 54.6 U.S. government sponsored agencies 74.9 0.1 (0.2 ) 74.8 Foreign government obligations 4.6 — — 4.6 Marketable equity securities 29.4 2.7 (0.7 ) 31.4 327.3 2.9 (1.5 ) 328.7 Long-term investments: Marketable equity securities 54.5 574.2 — 628.7 Asset-backed securities 0.3 — (0.1 ) 0.2 54.8 574.2 (0.1 ) 628.9 Total $ 382.1 $ 577.1 $ (1.6 ) $ 957.6
Summary of fair value of gross unrealized losses for investments with unrealized losses	The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): March 31, December 31, 2015 Fair value of investments in a loss position 12 months or more $ 9.5 $ 10.4 Fair value of investments in a loss position less than 12 months $ 97.6 $ 204.0 Gross unrealized losses for investments in a loss position 12 months or more $ 0.3 $ 0.4 Gross unrealized losses for investments in a loss position less than 12 months $ 0.7 $ 1.2
Discussion of current derivative risk management	The following is a summary of our forward foreign exchange contracts (in millions): March 31, 2016 Contracts maturing in April through June 2016 to sell foreign currency: Notional value $ 16.1 Unrealized gain $ 0.1 Contracts maturing in April through June 2016 to purchase foreign currency: Notional value $ 337.2 Unrealized loss $ (1.6 )
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date	The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2016 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 101.3 $ 101.4 Mature in one to five years 154.4 154.8 Mature in more than five years 55.1 55.8 Total $ 310.8 $ 312.0
Estimated fair value of financial instruments	The estimated fair value of the financial instruments discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): March 31, 2016 December 31, 2015 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Other investments $ 86.5 $ 831.8 2 $ 86.5 $ 843.2 2 Total long-term debt, excluding leases and current maturities $ 422.0 $ 455.6 2 $ 421.9 $ 454.3 2

4. Intangible Assets, Goodwi21

4. Intangible Assets, Goodwill and Other (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Changes to goodwill by segment	Changes to goodwill by segment were as follows (in millions): Life Science Clinical Diagnostics Total Balances as of January 1, 2016: Goodwill $ 207.2 $ 316.9 $ 524.1 Accumulated impairment losses (27.2 ) (1.0 ) (28.2 ) Goodwill, net 180.0 315.9 495.9 Acquisitions 2.8 — 2.8 Currency fluctuations 0.5 10.4 10.9 Balances as of March 31, 2016: Goodwill 210.5 327.3 537.8 Accumulated impairment losses (27.2 ) (1.0 ) (28.2 ) Goodwill, net $ 183.3 $ 326.3 $ 509.6
Schedule of identifiable purchased intangible assets with definite lives	Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): March 31, 2016 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 2-9 $ 88.3 $ (50.4 ) $ 37.9 Know how 1-10 187.6 (129.8 ) 57.8 Developed product technology 3-13 134.9 (52.1 ) 82.8 Licenses 3-10 39.6 (29.2 ) 10.4 Tradenames 5-8 3.6 (2.5 ) 1.1 Covenants not to compete 3-10 7.8 (1.9 ) 5.9 Total definite-lived intangible assets 461.8 (265.9 ) 195.9 In-process research and development 46.4 — 46.4 Total purchased intangible assets $ 508.2 $ (265.9 ) $ 242.3 December 31, 2015 Average Remaining Life (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 2-10 $ 84.7 $ (46.8 ) $ 37.9 Know how 1-10 184.0 (121.6 ) 62.4 Developed product technology 4-12 101.3 (48.9 ) 52.4 Licenses 3-10 39.2 (28.5 ) 10.7 Tradenames 5-9 3.5 (2.4 ) 1.1 Covenants not to compete 3-7 4.8 (1.7 ) 3.1 Total definite-lived intangible assets 417.5 (249.9 ) 167.6 In-process research and development 46.4 — 46.4 Total purchased intangible assets $ 463.9 $ (249.9 ) $ 214.0
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended March 31, 2016 2015 Amortization expense $ 9.4 $ 9.2

5. Product Warranty Liability

5. Product Warranty Liability (Tables)	3 Months Ended
	Mar. 31, 2016
Product Warranties Disclosures [Abstract]
Components of warranty accrual	Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets, were as follows (in millions): January 1, 2016 $ 17.4 Provision for warranty 8.1 Actual warranty costs (7.4 ) March 31, 2016 $ 18.1

6. Long-Term Debt (Tables)

6. Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	The principal components of long-term debt are as follows (in millions): March 31, December 31, 2015 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (3.0 ) (3.1 ) Long-term debt less unamortized discount and debt issuance costs 422.0 421.9 Capital leases and other debt 12.3 12.3 434.3 434.2 Less current maturities (0.3 ) (0.3 ) Long-term debt $ 434.0 $ 433.9

7. Accumulated Other Compreh24

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2016
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding losses on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2016: $ 33.7 $ (20.7 ) $ 369.1 $ 382.1 Other comprehensive income (loss), before reclassifications 37.9 (0.9 ) (6.5 ) 30.5 Amounts reclassified from Accumulated other comprehensive income — 0.3 — 0.3 Income tax effects — — 2.4 2.4 Other comprehensive income (loss), net of income taxes 37.9 (0.6 ) (4.1 ) 33.2 Balances as of March 31, 2016: $ 71.6 $ (21.3 ) $ 365.0 $ 415.3 Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income Balances as of January 1, 2015: $ 71.2 $ (16.3 ) $ 164.0 $ 218.9 Other comprehensive (loss) income, before reclassifications (19.5 ) 0.9 11.2 (7.4 ) Amounts reclassified from Accumulated other comprehensive income — 0.2 (0.3 ) (0.1 ) Income tax effects — — (4.0 ) (4.0 ) Other comprehensive (loss) income, net of income taxes (19.5 ) 1.1 6.9 (11.5 ) Balances as of March 31, 2015: $ 51.7 $ (15.2 ) $ 170.9 $ 207.4
Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block]	The amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows: Income before taxes impact (in millions): Three Months Ended March 31, Components of Comprehensive income 2016 2015 Location Amortization of foreign other post-employment benefit items $ (0.3 ) $ (0.2 ) Selling, general and administrative expense Net holding gains on available-for-sale investments $ — $ 0.3 Other (income) expense, net Reclassification adjustments are calculated using the specific identification method.

8. Earnings Per Share (Tables)

8. Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares	The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended March 31, 2016 2015 Basic weighted average shares outstanding 29,364 29,092 Effect of potentially dilutive stock options and restricted stock awards 142 197 Diluted weighted average common shares 29,506 29,289 Anti-dilutive shares 90 106

9. Other Income and Expenses (

9. Other Income and Expenses (Tables)	3 Months Ended
	Mar. 31, 2016
Other Income and Expenses [Abstract]
Schedule of other income (expense), net	Other (income) expense, net includes the following components (in millions): Three Months Ended March 31, 2016 2015 Interest and investment income $ (1.2 ) $ (0.9 ) Net realized gain on investments — (0.3 ) Other (income) expense, net $ (1.2 ) $ (1.2 )

11. Segment Information (Table

11. Segment Information (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Reporting [Abstract]
Information regarding industry segments	Information regarding industry segments for the three months ended March 31, 2016 and 2015 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2016 $ 165.9 $ 301.7 $ 3.6 2015 $ 155.9 $ 313.6 $ 3.3 Segment net (loss) profit 2016 $ (3.3 ) $ 24.8 $ 0.3 2015 $ (2.4 ) $ 35.2 $ (0.1 )
Reconciliation of segment profit to consolidated income before taxes	following reconciles total segment profit to consolidated income before taxes (in millions): Three Months Ended March 31, 2016 2015 Total segment profit $ 21.8 $ 32.7 Foreign currency exchange losses, net (1.1 ) (3.8 ) Net corporate operating, interest and other expense not allocated to segments (1.7 ) (3.4 ) Other income (expense), net 1.2 1.2 Consolidated income before income taxes $ 20.2 $ 26.7

1. Basis of Presentation and28

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net of current maturities	$ 433,980	$ 433,883
Other assets	$ 65,640	64,618
Adjustments for New Accounting Pronouncement [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt, net of current maturities		1,800
Other assets		$ 1,800

2. Acquisitions (Details)

2. Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Jan. 06, 2016	Dec. 31, 2015	Apr. 10, 2014
Business Acquisition [Line Items]
Goodwill	$ 509,582		$ 495,948
Goodwill, Acquired During Period	2,800
Analytical Flow Cytometer Platform [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred	38,800
Business Combination, Contingent Consideration, Liability	29,300	$ 29,300
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 36,000
Payments to Acquire Businesses, Net of Cash Acquired	9,500
Goodwill, Acquired During Period	2,800
GnuBIO [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability	$ 10,000			$ 10,700

3. Fair Value Measurements Fai

3. Fair Value Measurements Fair Value Level Table (Details) - USD ($) $ in Millions		Mar. 31, 2016	Jan. 06, 2016	Dec. 31, 2015
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		$ 4.2		$ 4.2
Available-for-sale Securities, Fair Value Disclosure	[1]	965.6		957.6
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	0.9		0.9
Assets, Fair Value Disclosure		1,025.8		1,034.3
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	2.4		1.1
Business Combination, Contingent Consideration, Liability	[4]	43.6		19.1
Liabilities, Fair Value Disclosure		46		20.2
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		4.2		4.2
Available-for-sale Securities, Fair Value Disclosure	[1]	653.6		660.1
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	0		0
Assets, Fair Value Disclosure		671.9		687.5
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	0		0
Business Combination, Contingent Consideration, Liability	[4]	0		0
Liabilities, Fair Value Disclosure		0		0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0		0
Available-for-sale Securities, Fair Value Disclosure	[1]	312		297.5
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	0.9		0.9
Assets, Fair Value Disclosure		353.9		346.8
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	2.4		1.1
Business Combination, Contingent Consideration, Liability	[4]	0		0
Liabilities, Fair Value Disclosure		2.4		1.1
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0		0
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[2]	0		0
Assets, Fair Value Disclosure		0		0
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[3]	0		0
Business Combination, Contingent Consideration, Liability	[4]	43.6		19.1
Liabilities, Fair Value Disclosure		43.6		19.1
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	5.4		14.6
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0		0
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	5.4		14.6
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0		0
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	35.6		33.2
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0		0
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	35.6		33.2
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0		0
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]			0.6
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]			0
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]			0.6
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]			0
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	9.8		11.9
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	9.8		11.9
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0		0
Foreign Time Deposits [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0		0
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	4.3		11.3
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	4.3		11.3
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0		0
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0		0
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	55.1		71.6
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	14.1		23.2
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	41		48.4
Cash Equivalents [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[5]	0		0
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	653.6		660.1
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	653.6		660.1
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	10.1		6.4
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	10.1		6.4
Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	5		4.6
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	5		4.6
Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	149.8		156.9
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	149.8		156.9
Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	78.5		74.8
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	78.5		74.8
US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	68.6		54.8
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	68.6		54.8
Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure	[1]	0		0
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		14.3		13.5
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		29.3		5.6
Short-term Investments [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		345		328.7
Short-term Investments [Member] | Marketable Equity Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		33.3		31.4
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		10.1		6.4
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		5		4.6
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		149.8		156.9
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		78.5		74.8
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		68.3		54.6
Other Investments [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Fair Value Disclosure		620.6		$ 628.9
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		29.3	$ 29.3
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0
[1]	Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2016 December 31, 2015Short-term investments$345.0 $328.7Other investments620.6 628.9Total$965.6 $957.6
[2]	Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.
[3]	Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.
[4]	Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2016 December 31, 2015Other current liabilities$14.3 $13.5Other long-term liabilities29.3 5.6 Total$43.6 $19.1
[5]	Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.

3. Fair Value Measurements 3.

3. Fair Value Measurements 3. Contingent Consideration (Details) - USD ($) $ in Millions		3 Months Ended	42 Months Ended
		Mar. 31, 2016	Mar. 31, 2016	Jan. 06, 2016	Dec. 31, 2015	Apr. 10, 2014	Sep. 30, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value		$ 33.6	$ 33.6		$ 9.1
CellSorter [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration milestone payments		(3.5)	(28.9)
(Decrease) increase in fair value of contingent consideration included in SGA		(1.3)	(11.4)
Business Combination, Contingent Consideration, Liability		4.3	4.3				$ 44.6
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		29.3	29.3	$ 29.3
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances		29.3
GnuBIO [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		$ 10	$ 10			$ 10.7
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		39.00%	39.00%
Credit Adjusted Discount Rates Lower [Member] | CellSorter [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Level 3 Inputs		.0068
Market Price of Risk [Member] | CellSorter [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Level 3 Inputs		.0130
Market Price of Risk [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Level 3 Inputs		.06
Projected Volatility of Growth Rate [Member] | CellSorter [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Level 3 Inputs		.15
Projected Volatility of Growth Rate [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Level 3 Inputs		.10
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		20.00%	20.00%
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0	$ 0
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	43.6	43.6		19.1
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		29.3	29.3		5.6
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		$ 14.3	$ 14.3		$ 13.5
[1]	Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2016 December 31, 2015Other current liabilities$14.3 $13.5Other long-term liabilities29.3 5.6 Total$43.6 $19.1

3. Foreign Exchange Forward Co

3. Foreign Exchange Forward Contracts (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)
Forward foreign exchange contract to sell foreign currency [Member]
Derivatives, Fair Value [Line Items]
Notional value	$ 16.1
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	0.1
Forward foreign exchange contract to purchase foreign currency [Member]
Derivatives, Fair Value [Line Items]
Notional value	337.2
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	$ (1.6)

3. Available-for-Sale Investme

3. Available-for-Sale Investments (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions		Mar. 31, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 396.5	$ 382.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		570.1	577.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(1)	(1.6)
Estimated Fair Value	[1]	965.6	957.6
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	149.8	156.9
Municipal obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	10.1	6.4
Asset-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	68.6	54.8
Marketable Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	653.6	660.1
US Government Sponsored Agencies [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	78.5	74.8
Foreign Government Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value	[1]	5	4.6
Other Long-term Investments [Member] | Asset-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		0.3	0.3
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	(0.1)
Estimated Fair Value		0.3	0.2
Other Long-term Investments [Member] | Marketable Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		54.5	54.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		565.8	574.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Estimated Fair Value		620.3	628.7
Other Long-term Investments [Member] | Available-for-sale Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		54.8	54.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		565.8	574.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	(0.1)
Estimated Fair Value		620.6	628.9
Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value		345	328.7
Short-term Investments [Member] | Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		149.3	157.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.7	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.2)	(0.4)
Estimated Fair Value		149.8	156.9
Short-term Investments [Member] | Municipal obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		10	6.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.1	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Estimated Fair Value		10.1	6.4
Short-term Investments [Member] | Asset-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		68.4	54.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.1	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.2)	(0.2)
Estimated Fair Value		68.3	54.6
Short-term Investments [Member] | Marketable Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		31.2	29.4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		2.7	2.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.6)	(0.7)
Estimated Fair Value		33.3	31.4
Short-term Investments [Member] | Available-for-sale Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		341.7	327.3
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		4.3	2.9
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(1)	(1.5)
Estimated Fair Value		345	328.7
Short-term Investments [Member] | US Government Sponsored Agencies [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		77.8	74.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.7	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	(0.2)
Estimated Fair Value		78.5	74.8
Short-term Investments [Member] | Foreign Government Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		5	4.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Estimated Fair Value		$ 5	$ 4.6
[1]	Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2016 December 31, 2015Short-term investments$345.0 $328.7Other investments620.6 628.9Total$965.6 $957.6

3. Amortized Cost and Fair Val

3. Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions	Mar. 31, 2016USD ($)
Fair Value Disclosures [Abstract]
Mature in less than one year	$ 101.3
Mature in one to five years	154.4
Mature in more than five years	55.1
Total Amortized Cost	310.8
Mature in less than one year	101.4
Mature in one to five years	154.8
Mature in more than five years	55.8
Estimated Fair Value	$ 312

3. Fair Value and Gross Unreal

3. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Tolerable variance Level 2 debt security pricing	1.00%
Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more	$ 9.5	$ 10.4
Cost Method Investment, Percentage Owned	35.00%
Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months	$ 97.6	204
Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0.3	0.4
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	$ 0.7	$ 1.2

3. Fair Value Financial Instru

3. Fair Value Financial Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Investments	$ 86.5	$ 86.5
Total long-term debt, excluding capital leases and current maturities	422	421.9
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Investments	831.8	843.2
Total long-term debt, excluding capital leases and current maturities	$ 455.6	$ 454.3

4. Intangible Assets, Goodwi37

4. Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
Goodwill	$ 537,800	$ 524,100
Accumulated impairment loss	(28,200)	(28,200)
Goodwill, net	509,582	495,948
Currency fluctuations	10,900
Goodwill, Acquired During Period	2,800
Life Science [Member]
Goodwill [Line Items]
Goodwill	210,500	207,200
Accumulated impairment loss	(27,200)	(27,200)
Goodwill, net	183,300	180,000
Currency fluctuations	500
Goodwill, Acquired During Period	2,800
Clinical Diagnostics [Member]
Goodwill [Line Items]
Goodwill	327,300	316,900
Accumulated impairment loss	(1,000)	(1,000)
Goodwill, net	326,300	$ 315,900
Currency fluctuations	10,400
Goodwill, Acquired During Period	$ 0

4. Intangible Assets, Goodwi38

4. Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 461.8	$ 417.5
Accumulated Amortization	(265.9)	(249.9)
Net Carrying Amount	195.9	167.6
Amortization [Abstract]
Amortization expense	9.4
Intangible Assets, Gross (Excluding Goodwill)	508.2	463.9
Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	88.3	84.7
Accumulated Amortization	(50.4)	(46.8)
Net Carrying Amount	37.9	37.9
Know how [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	187.6	184
Accumulated Amortization	(129.8)	(121.6)
Net Carrying Amount	57.8	62.4
Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	134.9	101.3
Accumulated Amortization	(52.1)	(48.9)
Net Carrying Amount	82.8	52.4
Licensing Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	39.6	39.2
Accumulated Amortization	(29.2)	(28.5)
Net Carrying Amount	10.4	10.7
Trade Names [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	3.6	3.5
Accumulated Amortization	(2.5)	(2.4)
Net Carrying Amount	1.1	1.1
Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	7.8	4.8
Accumulated Amortization	(1.9)	(1.7)
Net Carrying Amount	$ 5.9	$ 3.1
Minimum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	2 years	2 years
Minimum [Member] | Know how [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	1 year	1 year
Minimum [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	3 years	4 years
Minimum [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	3 years	3 years
Minimum [Member] | Trade Names [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	5 years	5 years
Minimum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	3 years	3 years
Minimum [Member] | Other Intangible Assets [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	0 years	0 years
Maximum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	9 years	10 years
Maximum [Member] | Know how [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	10 years	10 years
Maximum [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	13 years	12 years
Maximum [Member] | Licensing Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	10 years	10 years
Maximum [Member] | Trade Names [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	8 years	9 years
Maximum [Member] | Noncompete Agreements [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	10 years	7 years
Maximum [Member] | Other Intangible Assets [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Average Remaining Life (years)	0 years	0 years
In Process Research and Development [Member]
Amortization [Abstract]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 46.4	$ 46.4
Analytical Flow Cytometer Platform [Member] | Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	33
Analytical Flow Cytometer Platform [Member] | Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 3

5. Product Warranty Liabilit39

5. Product Warranty Liability (Details) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]
Accrual at beginning of period	$ 17.4
Provision for warranty	8.1
Actual warranty costs	(7.4)
Accrual at end of period	$ 18.1

6. Long-Term Debt (Details)

6. Long-Term Debt (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2010
Debt Instrument [Line Items]
Debt and Capital Lease Obligations	$ 434,300	$ 434,200
Less Current Maturities	(300)	(300)
Long-term debt, net of current maturities	433,980	433,883
Unsecured Debt [Member] | Senior Notes 4.875% due 2020, net of discount [Member]
Debt Instrument [Line Items]
Unsecured Debt	$ 425,000	425,000
Debt Instrument, Interest Rate, Stated Percentage			4.875%
Debt Instrument, Redemption Price, Percentage	100.00%
Long-term debt	$ 422,000	421,900	$ 422,600
Debt Instrument, Interest Rate, Effective Percentage			4.946%
Face amount of debt sold			$ 425,000
Debt Instrument, Unamortized Discount	(3,000)	(3,100)
Capital Lease Obligations [Member] | Capital Leases and Other Debt [Member]
Debt Instrument [Line Items]
Long-term Debt and Capital Lease Obligations, Including Current Maturities	12,300	$ 12,300
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	200,000
Outstanding borrowings	$ 0
Line of Credit Facility, Interest Rate at Period End	1.88%
Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	$ 800

7. Accumulated Other Compreh41

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Selling, general and administrative expense	$ (189,716)	$ (188,555)
Other (income) expense, net	(1,177)	(1,153)
Accumulated other comprehensive income	415,340		$ 382,138
Total other comprehensive income (loss) net of tax	33,202	(11,499)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	71,600	51,700	33,700	$ 71,200
Other Comprehensive Income (Loss), before Reclassifications, before Tax	37,900	(19,500)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	0	0
Other Comprehensive Income (Loss), Tax	0	0
Total other comprehensive income (loss) net of tax	37,900	(19,500)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	(21,300)	(15,200)	(20,700)	(16,300)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(900)	900
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	300	200
Other Comprehensive Income (Loss), Tax	0	0
Total other comprehensive income (loss) net of tax	(600)	1,100
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Selling, general and administrative expense	(300)	(200)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	365,000	170,900	369,100	164,000
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(6,500)	11,200
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	0	(300)
Other Comprehensive Income (Loss), Tax	2,400	(4,000)
Total other comprehensive income (loss) net of tax	(4,100)	6,900
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	0	(300)
Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	415,300	207,400	$ 382,100	$ 218,900
Other Comprehensive Income (Loss), before Reclassifications, before Tax	30,500	(7,400)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	300	(100)
Other Comprehensive Income (Loss), Tax	2,400	(4,000)
Total other comprehensive income (loss) net of tax	$ 33,200	$ (11,500)

8. Earnings Per Share (Details

8. Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Basic weighted average shares outstanding	29,364	29,092
Effect of potentially dilutive stock options and restricted stock awards	142	197
Diluted weighted average common shares	29,506	29,289
Anti-dilutive shares	90	106

9. Other Income and Expenses43

9. Other Income and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Interest and investment income	$ (1,200)	$ (900)
Net realized gain on investments	0	(300)
Other (income) expense, net	$ 1,177	$ 1,153

10. Income Taxes (Details)

10. Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Effective tax rate	39.00%	33.00%
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	$ 4
U.S. Federal [Member]
Statutory Rates	35.00%	35.00%

11. Segment Information (Detai

11. Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information [Line Items]
Net sales	$ 471,197	$ 472,821
Income before income taxes	20,195	26,694
Life Science [Member]
Segment Reporting Information [Line Items]
Net sales	165,900	155,900
Income before income taxes	(3,300)	(2,400)
Clinical Diagnostics [Member]
Segment Reporting Information [Line Items]
Net sales	301,700	313,600
Income before income taxes	24,800	35,200
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales	3,600	3,300
Income before income taxes	$ 300	$ (100)

11. Segment Profit Reconciliat

11. Segment Profit Reconciliation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ (20,195)	$ (26,694)
Foreign Currency Gain (Loss) [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	1,100	3,800
Corporate, Non-Segment [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(1,700)	(3,400)
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(21,800)	(32,700)
Other Nonoperating Income (Expense) [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ (1,200)	$ (1,200)